Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MiTiGate trial in myalgia temporomandibular disorder
ISRCTN12054536Phase 3Recruiting
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Sep 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of botulinum toxin type A, lidocaine, amitriptyline and gabapentin in Craniomandibular myalgia (3 arms), sponsored by Newcastle Hospitals NHS Foundation Trust. Primary endpoints: Characteristic pain intensity at 36 weeks, Disorder-specific quality of life at 36 weeks and 1 more. Started Sep 2024; status: recruiting.
02
Drugs
botulinum toxin type Alidocaineamitriptylinegabapentin
03
Conditions
Craniomandibular myalgia
Beyond the preview
Go deeper on ISRCTN12054536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12054536.